N2C Derm & Pain LP is a private equity fund based in New York, New York. According to its most recent Form D, filed Apr 4, 2019, it has sold $42,100,000 of interests to 3 investors since its first sale in Feb 2019. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Tjarko Hektor; Dan Townsend; Clay Cole.
- Total raised
- $42,100,000Cumulative sales reported on Form D
- Investors
- 3
- First sale
- Feb 26, 2019
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Tjarko Hektor; Dan Townsend; Clay Cole
- Latest Form D
- Apr 4, 2019
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Questions about N2C Derm & Pain LP
What is the minimum investment for N2C Derm & Pain LP?
N2C Derm & Pain LP's latest Form D, filed Apr 4, 2019, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in N2C Derm & Pain LP?
N2C Derm & Pain LP is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has N2C Derm & Pain LP raised?
N2C Derm & Pain LP reports $42,100,000 sold from 3 investors on its Form D filed Apr 4, 2019. This is cumulative sales since the offering began, not current assets or performance.
Where is N2C Derm & Pain LP based?
N2C Derm & Pain LP is based in New York, New York.
When did N2C Derm & Pain LP launch?
N2C Derm & Pain LP reports its first sale in Feb 2019.
Size compared with every private equity fund
Raised more than 69% of the 3,670 private equity funds based in New York, and more than 61% of all 8,975 that report sales.